



(51) International Patent Classification:

A61K 31/7105 (2006.01) A61P 35/00 (2006.01)
A61K 39/395 (2006.01) A61P 35/02 (2006.01)

(21) International Application Number:

PCT/US2024/036254

(22) International Filing Date:

28 June 2024 (28.06.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/511,274 30 June 2023 (30.06.2023) US
63/579,422 29 August 2023 (29.08.2023) US

(71) Applicant: **MYELOID THERAPEUTICS, INC.**
[US/US]; 300 Technology Square, Suite 203, Cambridge,
MA 02139 (US).

(72) Inventors; and

(71) Applicants: **GERBER, Michele, Luise**; c/o Myeloid Ther-
apeutics, Inc., 300 Technology Square, Suite 203, Cam-
bridge, MA 02139 (US). **MAURER, Matthew, Anthony**;

c/o Myeloid Therapeutics, Inc., 300 Technology Square,
Suite 203, Cambridge, MA 02139 (US).

(72) Inventors: **GETTS, Daniel**; c/o Myeloid Therapeutics,
Inc., 300 Technology Square, Suite 203, Cambridge, MA
02139 (US). **WANG, Yuxiao**; c/o Myeloid Therapeutics,
Inc., 300 Technology Square, Suite 203, Cambridge, MA
02139 (US).

(74) Agent: **GHOSH, Sanjukta** et al.; Wilson Sonsini Goodrich
& Rosati, 650 Page Mill Road, Palo Alto, CA 94304 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(54) Title: ENGINEERED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF




FIG. 1

(57) Abstract: Compositions and methods for making and using engineered cells, such as, engineered myeloid cells that express a chimeric fusion protein that has a binding domain capable to binding surface molecules on target cells such as diseased cells.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*